The five-year investment plan focuses on upgrading critical production infrastructure at the site, which serves as a core hub for active pharmaceutical ingredients. By refreshing key machinery and operational capacity, the company intends to insulate its drug substance manufacturing against international supply disruptions while scaling up for U.S. clients. This move underscores a broader industry shift toward regionalizing production to mitigate risks associated with volatile global trade environments.
Evonik Commits $100 Million to Expand Indiana Pharmaceutical Hub
Geopolitical instability is reshaping the pharmaceutical supply chain as Evonik Industries moves to secure its footprint in the American Midwest. The German specialty chemicals firm announced a $100 million capital infusion to modernize its Lafayette, Indiana facility, aiming to capture the rising demand for domestic contract manufacturing services.
Comments (0)
No comments yet. Be the first!